LANTERN PHARMA INC (LTRN) Stock Income Statement
NASDAQ:LTRN - Nasdaq - US51654W1018 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 22.22M | 17.88M | 14.43M | 12.59M | 5.91M | |||
| Research and Development | 16.13M | 11.89M | 8.60M | 7.57M | 2.24M | |||
| Selling, General, and Administrative Expenses | 6.09M | 5.98M | 5.83M | 5.02M | 3.66M | |||
| Operating Income | -22.22M | -17.88M | -14.43M | -12.59M | -5.91M | |||
| Interest Income/Expense | 742.40K | 765.40K | 200.00K | 120.00K | N/A | |||
| Other Income/Expense | 692.90K | 1.15M | -30.00K | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | 110.00K | N/A | |||
| Income Before Taxes | -20.78M | -15.96M | -14.26M | -12.36M | -5.91M | |||
| Net Income | -20.78M | -15.96M | -14.26M | -12.36M | -5.91M | |||
| EBITDA | -22.20M | -17.86M | -14.42M | -12.58M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.93 | -1.47 | -1.31 | -1.13 | -0.95 | |||
| Non GAAP EPS | -1.93 | -1.48 | -1.31 | -1.13 | N/A | |||
| Statistics | ||||||||
All data in USD